Table 2.
Engagement in OUD pharmacotherapy from the MINI (Visit 2) to the end of follow-up (Visit 3) by type of psychiatric disorder.
| Mean (SD) | Bipolar disorder (n = 51, BPD) |
Major depressive disorder (n = 85, MDD) |
Anxiety disorders (n = 121, AXD) |
No mental disorder (n = 336, NMD) |
Total (N = 593) |
|---|---|---|---|---|---|
| # Follow-up months | 14.5 (3.6) | 16.0 (6.5) | 16.3 (6.5) | 16.1 (5.7) | 16.0 (5.8) |
| # Follow-up months, median (IQR) | 15.0 (2.0) | 15.0 (2.0) | 15.0 (2.0) | 15.0 (2.0) | 15.0 (2.0) |
| % Follow-up months received any OUD pharmacotherapy***e | 60.1 (38.0) | 71.6 (39.1) | 62.4 (41.8) | 50.6 (45.3) | 56.9 (43.8) |
| % Follow-up months received buprenorphinec | 22.0 (37.4) | 9.4 (25.9) | 11.6 (30.0) | 10.5 (28.6) | 11.6 (29.5) |
| % Follow-up months received methadone***a,e | 35.1 (40.8) | 60.0 (45.1) | 45.2 (45.8) | 38.1 (45.3) | 42.4 (45.6) |
Notes: IQR: interquartile range; SD: standard deviation.
Group comparison at each visit based on ANOVA test for continuous variables (*p < 0.05, **p < 0.01, ***p < 0.001).
All pairwise comparisons: Tukey-Kramer method was used for continuous variables (a = BPD vs. MDD, b = BPD vs AXD, c = BPD vs NMD, d = MDD vs. AXD, e = MDD vs. NMD, f = AXD vs. NMD).